Why Is Inflammation Disease-Focused Celldex Therapeutics Stock Trading Higher Today?

Grand News Network | November 6, 2023

Celldex Therapeutics Inc (NASDAQ: CLDX) released topline results from its Phase 2 trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to antihistamines, including patients who received prior biologics

CSU is characterized by the occurrence of hives or wheals for six weeks or longer ...

Full story available on Benzinga.com

Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.

Disclaimer Press Release Banner